新业路 8号华联时代大厦 B 幢22层 电话: 0571-88362156 传真:0571-88362156 邮编:310016 北京国枫(杭州)律师事务所 关于振德医疗用品股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]G0009 号 致: 振德医疗用品股份有限公司(贵公司) 北京国枫(杭州)律师事务所(以下简称"本所")接受贵公司的委托,指派律师 出席并见证贵公司 2024年年度股东大会(以下简称"本次会议")。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称 "《股东会规则》")、《律师事务所从事证券法律业务管理办法》(以下简称"《证券法律 业务管理办法》")、《律师事务所证券法律业务执业规则(试行)》(以下简称"《证券法 律业务执业规则》")等相关法律、行政法规、规章、规范性文件及《振德医疗用品股份 有限公司章程》(以下简称"《公司章程》"）的规定,就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜,出具本法律意见书。 对本法律意见书 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [2][23]. Core Insights - The company reported a revenue of 4.264 billion yuan in 2024, reflecting a growth of 3.32%, while the net profit attributable to shareholders increased significantly by 94.14% to 385 million yuan [2][4]. - In Q1 2025, the company achieved a revenue of 999.2 million yuan, a growth of 2.87%, but the net profit decreased by 30.19% to 51 million yuan [2][4]. - The company has expanded its distribution channels, covering nearly 9,000 hospitals across China and achieving a 99% coverage rate in the top 100 retail pharmacy chains [8]. Financial Performance Summary - **2024 Financials**: Total revenue was 4.264 billion yuan, with a net profit of 385 million yuan. The core business, excluding isolation protective products, saw a revenue increase of 15.80% [4][8]. - **2025 Projections**: Expected revenue growth of 12.6% to 4.8 billion yuan, with net profit projected to reach 439 million yuan, a 14% increase [4][9]. - **Earnings Per Share (EPS)**: Projected EPS for 2025 is 1.65 yuan, with a price-to-earnings (P/E) ratio of 12 [4][9]. Market Expansion - The company has made significant strides in both domestic and international markets, with domestic revenue from core business growing by 18.08% and overseas revenue increasing by 14.64% [8]. - The company has established an international marketing center and is penetrating markets in Southeast Asia, the Middle East, North America, and South America [8]. Investment Recommendations - The report adjusts the net profit forecast for 2025-2027 to 440 million, 510 million, and 590 million yuan respectively, with corresponding P/E ratios of 12, 10, and 9 [8][9]. - A discounted cash flow (DCF) model estimates the company's overall valuation at 7.5 billion yuan, leading to a target price of approximately 28 yuan per share [8].

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [2][4][23]. Core Insights - The company reported a revenue of 4.264 billion yuan in 2024, reflecting a growth of 3.32%, while the net profit attributable to shareholders increased significantly by 94.14% to 385 million yuan [2][4]. - In Q1 2025, the company achieved a revenue of 992 million yuan, a year-on-year increase of 2.87%, but the net profit decreased by 30.19% to 51 million yuan [2][4]. - The company has expanded its distribution channels, covering nearly 9,000 hospitals across China and achieving a 99% coverage rate in the top 100 chain pharmacies [8]. Financial Performance Summary - **2024 Financials**: Total revenue was 4.264 billion yuan, with a net profit of 385 million yuan. The core business revenue, excluding isolation protective products, grew by 15.80% [4][8]. - **2025 Projections**: Expected revenue growth of 12.6% to 4.8 billion yuan, with net profit projected to reach 439 million yuan, a 14% increase [4][9]. - **Earnings Per Share (EPS)**: Projected EPS for 2025 is 1.65 yuan, with a price-to-earnings (P/E) ratio of 12 [4][9]. Market Expansion - The company has seen robust growth in both domestic and international markets, with overseas revenue reaching 2.475 billion yuan in 2024, a 14.64% increase [8]. - The company has established an international marketing center and is making inroads into North and South American markets [8]. Investment Recommendations - The report adjusts the net profit forecast for 2025-2027 to 440 million, 510 million, and 590 million yuan respectively, with corresponding P/E ratios of 12, 10, and 9 [8][9]. - A discounted cash flow (DCF) model estimates the company's overall valuation at 7.5 billion yuan, leading to a target price of approximately 28 yuan per share [8].

截至2025年5月9日收盘，振德医疗(603301)报收于19.42元，下跌0.87%，换手率1.06%，成交量2.83万 手，成交额5501.15万元。 当日关注点 交易信息汇总 5月9日，振德医疗的资金流向情况如下：主力资金净流入469.81万元，占总成交额8.54%；游资资金净 流出1250.8万元，占总成交额22.74%；散户资金净流入780.98万元，占总成交额14.2%。 2024年，公司实现营业收入42.64亿元，同比增长3.32%，归属于母公司所有者的净利润3.85亿元，同比 增长94.14%。 公司公告汇总 振德医疗用品股份有限公司将于2025年5月19日下午14点00分在浙江省绍兴市越城区皋埠街道香积路55 号召开2024年年度股东大会。会议将审议以下议案：- 公司2024年度董事会工作报告- 监事会工作报告- 年度报告全文及其摘要- 财务决算报告- 利润分配方案：公司计划以266,321,760股为基数，每10股派发 现金红利6.50元（含税），合计派发现金红利173,109,144元（含税）- 开展远期外汇交易业务：年度总 金额不超过35,000万美元- 申请综合授信额度暨为子公司提供 ...

Core Viewpoint - Zhendemedical (603301) has shown a positive performance with a stock price increase of 1.46% this week, closing at 19.42 yuan, reflecting a stable growth trend in the medical device sector [1] Company Announcements - Zhendemedical will hold its 2024 Annual General Meeting on May 19, 2025, to review several proposals including the 2024 Board of Directors' report, Supervisory Board report, annual report, financial settlement report, profit distribution plan, and other business matters [1][3] - The company plans to conduct forward foreign exchange trading with a total annual amount not exceeding 35 million USD and will seek a comprehensive credit facility from financial institutions not exceeding 200 million RMB [2][3] - The company intends to reappoint Tianjian Accounting Firm for the 2025 financial audit and internal control audit [2][3] Performance Disclosure Highlights - In 2024, Zhendemedical achieved an operating income of 4.264 billion yuan, representing a year-on-year growth of 3.32%, while the net profit attributable to the parent company was 385 million yuan, showing a significant year-on-year increase of 94.14% [1][3] - The company plans to distribute a cash dividend of 6.50 yuan (including tax) for every 10 shares, totaling 173.11 million yuan (including tax) [1][3]

Meeting Agenda - The 2024 Annual General Meeting of Shareholders will cover various reports including the independent director's report, financial settlement report, profit distribution proposal, and proposals for foreign exchange trading and credit limits for subsidiaries [1][2][3] Company Performance - In 2023, the company achieved a revenue of 4.264 billion yuan, a 3.32% increase year-on-year, with a net profit attributable to shareholders of 385 million yuan, a 94.14% increase [4][5] - The revenue from isolation protective products was 160 million yuan, a decrease of 4.23 billion yuan year-on-year, while excluding these products, the revenue grew by 15.80% [4][5] Market Strategy - The company focuses on core areas such as surgical infection control and rehabilitation, enhancing market competitiveness through strategic planning and operational efficiency [6][7] - The company has expanded its coverage to nearly 9,000 hospitals across China, with over 1,200 being top-tier hospitals [6] Retail Market Development - The company has achieved a retail revenue of 594 million yuan, with a 9.77% increase year-on-year when excluding isolation protective products [8] - The company has established a strong presence in both online and offline retail channels, covering 99% of the top 100 pharmacy chains in China [7][8] International Expansion - The company is actively developing production bases in Africa and Mexico to enhance its international market competitiveness and meet diverse supply chain needs [9][10] - The overseas revenue reached 2.475 billion yuan, a 14.64% increase year-on-year, driven by strong performance in Southeast Asia and the Middle East [10] Research and Development - The company has focused on innovative product development in areas such as wound care and infection control, with significant investments in R&D [11][12] - The company has obtained 9 new medical device registrations and 28 patents, totaling 105 patents and 136 medical device registrations [12] Governance and Compliance - The board of directors has adhered to legal regulations and company bylaws, ensuring compliance and effective decision-making [19][20] - The company has implemented a profit distribution plan, distributing a total of 133.16 million yuan in cash dividends [21] Future Plans - The company aims to enhance its governance structure, expand market penetration, and strengthen R&D investments in 2025 [22][23] - The company will focus on product strategy, brand building, and digital transformation to improve operational efficiency and market presence [24][25]

振德医疗 2024 年年度股东大会材料 2025 年 5 月 19 日 第 2页 共 59 页 振德医疗 2024 年年度股东大会材料 振德医疗用品股份有限公司 2024 年年度股东大会会议材料目录 第 3页 共 59 页 一、2024 年年度股东大会会议议程 二、2024 年年度股东大会会议须知 三、《公司 2024 年度董事会工作报告》 四、《公司 2024 年度监事会工作报告》 五、《关于<公司 2024 年度报告全文及其摘要>的提案》 六、《公司 2024 年度独立董事述职报告》 七、《公司 2024 年度财务决算报告》 八、《关于公司 2024 年度利润分配方案》 九、《关于公司开展远期外汇交易业务的提案》 十、《关于公司 2025 年度申请综合授信额度暨在授信额度内为子公 司提供担保的提案》 十一、《关于续聘会计师事务所的提案》 振德医疗 2024 年年度股东大会材料 振德医疗用品股份有限公司 2024 年年度股东大会会议材料 振德医疗用品股份有限公司 2024 年年度股东大会会议议程 一、现场会议时间及地点 1、时间：2025 年 5 月 19 日（星期一）下午 14 点 00 分。 2、地点： ...

振德医疗用品股份有限公司 2024 年度独立董事述职报告 作为振德医疗用品股份有限公司（以下简称"公司"）独立董事， 在 2024 年度的工作中，本人严格按照《公司法》、《证券法》、《上 市公司独立董事管理办法》及其他有关法律法规和《公司章程》、《公 司独立董事工作制度》等规定和要求，凭借自身丰富的专业知识和经 验，积极参加公司股东大会、董事会会议以及各专门委员会会议，对 会议审议的重大事项，提出专业建议，为董事会的科学决策提供有力 支撑，促进公司规范运作，切实维护公司利益和全体股东特别是中小 股东的合法权益。现将 2024 年度履行职责情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 李生校先生，出生于 1962 年 5 月，中国国籍，无境外永久居 留权，硕士研究生学历；历任绍兴文理学院教授、经贸系党支部书记、 经管系主任、经管学院常务副院长、经济与管理学院院长、党总支副 书记、绍兴文理学院越商研究院院长、绍兴文理学院区域发展研究中 心主任、浙江富润数字科技股份有限公司独立董事、河南科隆新能源 股份有限公司独立董事；现任公司独立董事，中国心连心化肥有限公 司独立董事，会稽山绍兴酒 ...

振德医疗用品股份有限公司 2024 年度独立董事述职报告 作为振德医疗用品股份有限公司（以下简称"公司"）独立董事， 在 2024 年度的工作中，本人严格按照《公司法》、《证券法》、《上 市公司独立董事管理办法》及其他有关法律法规和《公司章程》、《公 司独立董事工作制度》等规定和要求，恪尽职守、勤勉尽责，积极参 加公司各项会议，利用自身的专业优势为公司发展提出建议，切实维 护公司利益和全体股东特别是中小股东的合法权益。现将 2024 年度 履行职责情况报告如下： 一、独立董事的基本情况 （二）独立性情况的说明 作为公司的独立董事，本人未在公司担任除独立董事以外的任何 职务，也未在公司主要股东单位担任任何职务，与公司以及主要股东 之间不存在利害关系或者其他可能妨碍进行独立客观判断的关系，不 存在任何影响担任公司独立董事独立性的关系，符合《上市公司独立 董事管理办法》、《上海证券交易所上市公司自律监管指引第 1 号— 规范运作》中对独立董事独立性的相关要求。 （一）工作履历、专业背景以及兼职情况 二、年度履职情况 （一）本年度会议出席情况 倪崖先生，出生于 1961 年 11 月，中国国籍，无境外永久居留 权，二 ...

振德医疗用品股份有限公司 2024 年度独立董事述职报告 作为振德医疗用品股份有限公司（以下简称"公司"）独立董事， 在 2024 年度的工作中，本人严格按照《公司法》、《证券法》、《上 市公司独立董事管理办法》及其他有关法律法规和《公司章程》、《公 司独立董事工作制度》等规定和要求，忠实履行独立董事职责，积极 参加公司股东大会、董事会会议以及各专门委员会会议，认真审议各 项议案，并利用自身的专业知识对相关议案发表意见，有效保证了董 事会的科学决策以及规范运作，切实维护公司利益和全体股东特别是 中小股东的合法权益。现将 2024 年度履行职责情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 朱茶芬女士，出生于 1980 年 4 月，中国国籍，无境外永久居 留权，博士研究生学历，注册会计师、高级会计师；历任浙江大学管 理学院博士后、助理研究员,北京数码视讯科技股份有限公司独立董 事，长虹塑料集团英派瑞塑料股份有限公司独立董事、杭州可靠护理 用品股份有限公司独立董事；现任公司独立董事，浙江大学管理学院 副教授，杭州广立微电子股份有限公司独立董事，浙江中控信息产业 股份有限公司独立董事, ...